USFDA approves Zydus menopause drug patch
In short
Zydus Lifesciences got final US FDA approval for a menopause treatment patch. The product is Estradiol and Levonorgestrel Transdermal System at 0.045 mg/0.015 mg per day.
This means the company can move ahead with the approved drug in the US. The report does not say when it will be sold or how much it could earn.
What the reporting says
Zydus Lifesciences received final US Food and Drug Administration approval for Estradiol and Levonorgestrel Transdermal System, with strengths of 0.045 mg/0.015 mg per day, according to a BusinessLine summary. The reporting identifies it as a menopause treatment drug, but it does not state launch timing, sales potential or any commercial terms. The immediate effect is regulatory clearance for the product, while market impact remains unspecified.
Why it matters
Zydus Lifesciences received final US FDA approval for Estradiol and Levonorgestrel Transdermal System at 0.045 mg/0.015 mg per day. The summary identifies it as a menopause treatment drug, but it does not state launch timing, pricing, sales estimates or manufacturing details. The approval is a positive regulatory step for Zydus, though the commercial impact is not yet stated.